Monday, August 4, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Biology

Insilico Medicine unveils quantum-assisted approach to designing drugs from fragments

April 18, 2024
in Biology
Reading Time: 5 mins read
0
QFASG Pipeline
67
SHARES
613
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT
ADVERTISEMENT

A groundbreaking new algorithm called Quantum-assisted Fragment-based Automated Structure Generator (QFASG) from a team of researchers at clinical stage artificial intelligence (AI)-driven biotech company Insilico Medicine (“Insilico”) offers a meaningful step forward in automated drug design. QFASG utilizes advanced chemoinformatic techniques to construct novel small-molecule structures from a library of molecular fragments. To demonstrate its effectiveness, the researchers successfully applied QFASG to generate new small-molecule inhibitors of two pharmacological targets involved in cancer pathogenesis. The findings were published in Frontiers in Chemistry. 

QFASG Pipeline

Credit: Insilico Medicine

A groundbreaking new algorithm called Quantum-assisted Fragment-based Automated Structure Generator (QFASG) from a team of researchers at clinical stage artificial intelligence (AI)-driven biotech company Insilico Medicine (“Insilico”) offers a meaningful step forward in automated drug design. QFASG utilizes advanced chemoinformatic techniques to construct novel small-molecule structures from a library of molecular fragments. To demonstrate its effectiveness, the researchers successfully applied QFASG to generate new small-molecule inhibitors of two pharmacological targets involved in cancer pathogenesis. The findings were published in Frontiers in Chemistry. 

In recent years, AI-assisted generative chemistry platforms such as Insilico’s Chemistry42 engine – a software platform for de novo small molecule design and optimization that integrates AI techniques with computational and medicinal chemistry methodologies – have demonstrated the possibility of designing novel drug candidates from scratch using generative AI. Now, driven by advances in quantum computing and chemoinformatic techniques, researchers can explore vast chemical spaces with new speed and efficiency, allowing them to design new compounds from virtual fragments. 

“QFASG generates new drug-like structures using a medicinal chemistry approach,” says Sergei Evteev, a lead researcher on the project. “By leveraging molecular fragments and advanced algorithms, we can design compounds that interact specifically with target proteins, potentially leading to detection of new promising chemotypes.”

One of the key features of QFASG is its fully automated pipeline, which streamlines the process of structure generation and optimization. The algorithm employs a two-part approach: first, probes are strategically placed within target binding sites, and then structural growth occurs through iterative modules, resulting in the generation of diverse compound libraries.

“Our goal with QFASG is to provide researchers with a powerful tool for generating primary hit compounds,” says Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine and a member of the research team. “These initial structures can serve as starting points for further optimization and development, ultimately accelerating the drug discovery process.”

To demonstrate the effectiveness of QFASG, the researchers used the algorithm to design inhibitors for two proteins that hold promise as targets for new cancer treatments: ATM and CAMKK2 kinases. ATM kinase is involved in DNA damage response and repair and is a promising target for the treatment of solid tumors, glioblastoma, sarcoma, lung, prostate and colorectal cancer and other pathologies. CAMKK2 plays a significant role in various physiological and pathological processes, including cancer cell growth and is overexpressed in multiple tumor types, including prostate, breast, ovarian, gastric and hepatic cancers 

In order to test the capabilities of QFASG, the researchers performed insilico validation by reproducing binding poses of known protein ligands and in vitro evaluation of structures generated for ATM and CAMKK2. In both cases, three unique structures designed by the algorithm were selected for synthesis and testing and several compounds demonstrated low micromolar activity against the desired targets. 

The researchers will continue to explore the use of QFASG for de novo generation of novel chemical structures – in particular to generate primary hit compounds and initial hypotheses that can be further explored in AI-driven generative chemistry platforms.

Insilico is a pioneer in using generative AI for drug discovery and development. The Company first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal in 2016. Then, Insilico developed and validated multiple approaches and features for its generative adversarial network (GAN)-based AI platform and integrated those algorithms into the commercially available Pharma.AI platform, which includes generative biology, chemistry, and medicine and has been used to produce a robust pipeline of promising therapeutic assets in multiple disease areas, including fibrosis, cancer, immunology and aging-related diseases, a number of which have been licensed. Since 2021, Insilico has nominated 18 preclinical candidates in its comprehensive portfolio of over 30 assets and has advanced six pipelines to the clinical stage. In March 2024, the Company published a paper in Nature Biotechnology that discloses the raw experimental data and the preclinical and clinical evaluation of its lead drug – a potentially first-in-class TNIK inhibitor for the treatment of idiopathic pulmonary fibrosis discovered and designed using generative AI that is currently in Phase II trials with patients. 

 

About Insilico Medicine

Insilico Medicine, a global clinical-stage biotechnology company powered by generative AI, connects biology, chemistry, and clinical trial analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and generating novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com



Journal

Frontiers in Chemistry

DOI

10.3389/fchem.2024.1382512

Article Title

Quantum-assisted fragment-based automated structure generator (QFASG) for small molecule design: an in vitro study

Article Publication Date

3-Apr-2024

Share27Tweet17
Previous Post

Janelia scientists release state-of-the-art spike-sorting software Kilosort4

Next Post

Targeting vulnerability in B-cell development leads to novel drug combination for leukemia

Related Posts

blank
Biology

Tracing Ancient Arthropod Movements: Decoding the Hidden Steps of Burgess Shale Trilobites

August 4, 2025
blank
Biology

Kinesin HUG1/2 Drive Male Germ Unit Transport

August 4, 2025
blank
Biology

Epigallocatechin-3-Gallate Blocks Influenza by Restoring Host Genes

August 4, 2025
blank
Biology

New Real-Time Method Detects Parasites in Food

August 4, 2025
blank
Biology

Midwestern Butterfly Survey Reveals Troubling Trends and Insightful Clues Through Big Data Analysis

August 4, 2025
blank
Biology

Immune Gene Response in Pufferfish Spleen Post-Infection

August 4, 2025
Next Post
Jun J. Yang and Jiyang Yu

Targeting vulnerability in B-cell development leads to novel drug combination for leukemia

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27529 shares
    Share 11008 Tweet 6880
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    939 shares
    Share 376 Tweet 235
  • Bee body mass, pathogens and local climate influence heat tolerance

    640 shares
    Share 256 Tweet 160
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    506 shares
    Share 202 Tweet 127
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    310 shares
    Share 124 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • UCLA Researchers Engineer Stem Cells to Generate Renewable Cancer-Fighting T Cells
  • Research Reveals Significant Health Insurance Disparities Among Certain Adopted Children
  • Tracing Ancient Arthropod Movements: Decoding the Hidden Steps of Burgess Shale Trilobites
  • Key Factors Driving Substance Abuse in Med Students

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 5,184 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading